BIAF bioAffinity Technologies, Inc.
$7.95▼ -15.34%
Healthcare
Other
After hours
$7.90▼ -0.63%
Sep 11, 7:59 PM ET
Volume 812.5K
Avg Volume (10D) 14.63M
Key Metrics & Fundamentals
Market Cap
$4.78M
P/E Ratio
–
Div Yield
–%
52W Range
4.56 - 202.50
% vs 50 MA
-9.96%
% vs 200 MA
-63.73%
RSI-14
48.3
MACD Histogram
+0.4600
Beta (1Y vs SPY)
2.19
Free Cash Flow
-$3.29M
Gross Rev
$1.51M
Gross Profit
$422,742
EBITDA
-$3.29M
COGS
$1.09M
Operating Exp
$3.76M
Operating Income
-$3.33M
EBIT
-$3.33M
Pretax Income
-$3.37M
Net Income
-$3.37M
EPS (Diluted)
-9.60
Price & Volume History
Loading chart…
Recent News
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
Business Wire · Sep 9, 2026 12:00 PM
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right?
Insider Monkey · Sep 5, 2026 6:13 AM
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · Sep 3, 2026 8:30 PM
bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update
InvestorsHub · Sep 3, 2026 12:21 PM
BC-Most Active Stocks
Associated Press · Sep 2, 2026 2:30 PM
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance
InvestorsHub · Sep 1, 2026 3:03 PM
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
Business Wire · Sep 1, 2026 12:00 PM
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
Business Wire · Aug 20, 2026 12:00 PM
bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung
InvestorsHub · Aug 18, 2026 2:43 PM
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
Business Wire · Aug 18, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See BIAF's money flow as a full page
Social Sentiment
No Reddit posts found for BIAF.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.